米氮平治疗伴失眠的抑郁症的临床疗效观察

目的 了解米氮平治疗伴失眠的抑郁症的疗效及安全性.方法 将60例伴失眠的抑郁症患者随机分为两组,分别用米氮平和西酞普兰治疗,疗程6周.采用汉密尔顿抑郁量表（HAMD）,临床疗效总评量表（CGI）和副反应量表（TESS）评定疗效和不良反应.结果 米氮平和西酞普兰在治疗抑郁症疗效相仿,无显著差异（P＞0.05）;不良反应发生率无统计学意义（P＞0.05）.结论 米氮平是一种安全有效,见效快,副作用小的药物,且对失眠有更好疗效.

Clinical efficacy observation on Mirtazapine in treatment of depression patients with insomnia symptom

Objective To investigate the efficacy and safety of Mirtazapine in the treatment of depression patients with insomnia symptom. Methods 60 depression patients with insomnia symptom were divided into two groups. They were assigned to receive mirtazapine or citalopram. All patients were observed for 6 weeks. The patients were assessed with Hamilton depressive scale（HAMD）, clinical global impression （CGI） and treatment emergent symptom scale （TESS）. Results The efficacy and side effect of both drugs were no significant differences in the scores of hamilton depressive scale and clinical global impression （ P 〉 0. 05 ）. Conclusions Mirtazapine is a safe and effective drug for depressive with more rapid onset of action and less side effects and better effective drug for insomnia than Citalopram.